Original news and analysis on international IP policy
The United States Chamber of Commerce sixth annual International IP Index, released yesterday, highlights positive developments in 50 economies to better protect intellectual property rights so as to reward creativity and innovation. But it also takes aim at practices the US industry group still sees as counterproductive.
Every year at this time, the Office of the United States Trade Representative collects comments from stakeholders for its review of how well US trading partners are behaving when it comes to protecting and enforcing the intellectual property rights of US companies. Pharmaceutical companies and an alliance of rights holding industries came prepared with a list of countries to be put on special watch lists, including Canada, Brazil, India, Malaysia, and Switzerland. A patient group, on the other hand, asked that trade interests not supersede access to medicines worldwide.
The unexpected announcement in December of the resignation of the Medicines Patent Pool executive director left the Pool searching for its new head. Marie-Paule Kieny, former World Health Organization assistant director general, now chair of the MPP governance board stepped in to oversee the MPP while the search goes on. She sat down recently for an interview with Intellectual Property Watch to explain that MPP is conducting business as usual, and is keeping firm in its plan to release the results of a feasibility study analysing the possibility for MPP to extend its licensing activities to other essential medicines still under patent.
World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job.
Are you an African woman entrepreneur seeking to advance your leadership, strategy, and business management skills? Are you interested in connecting with other women business owners from across the continent and being coached by a mentor?
Following a promise made at the beginning of his tenure to meet with the press regularly, World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference today to paint a picture of what has been done under his leadership for the last seven months. He highlighted the establishment of the WHO General Programme of Work for 2019-2023, the quest for a new resource mobilisation strategy, measures taken on emergencies, and the push for universal health coverage. He also answered questions about the WHO nomination of President Mugabe that was cut short, and an appointment in his leadership team.
A consortium including the Drugs for Neglected Disease initiative has launched a groundbreaking open source drug discovery project as way to find new drugs to treat mycetoma, a "devastating disease for which current treatments are ineffective, expensive, and toxic," the group said.
Gavin Keeney writes: As a type of historical morality tale, especially given arguments currently before the European Commission regarding copyright reform and “neighboring rights,” this short treatise addresses the origins of copyright in the Venetian Renaissance in the late 1400s under the aegis of privilegio, notably first granted to authors (author-publishers) versus printers (printer-publishers). Subsequently, printers as publishers would command the lion’s share of such rights to works. Arguably, Venetian privilege transferred the immemorial aspect of written works (here considered “moral rights” for works) to authors in a casual, yet emphatic manner leading to modern copyright. With contemporary copyright nominally belonging to authors, but in fact belonging by expropriation to presses and platforms, it is likely that one of the few solutions, short of benevolent presses fully sharing rights with authors, is for moral rights to return to works by way of the author renouncing copyright but refusing the arrogation of such renounced rights to presses and platforms.
A newly leaked 2016 letter from the CEO of Novartis to the president of Colombia, made available by Swiss group Public Eye, shows the level of concern the Swiss pharmaceutical company had over the effect of possible issuance of a compulsory licence for Novartis drug Glivec in the pivotal South American economy.
BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need.
By a vote of 94-0, the United States Senate on 5 February confirmed California intellectual property litigator Andrei Iancu as next director of the US Patent and Trademark Office (USPTO). The new Under Secretary of Commerce for Intellectual Property is currently managing partner of Irell & Manella LLP’s Los Angeles firm. The patent and trademark communities wished Iancu luck but said there are many issues at the agency that need his attention.
Vaccination will help prevent some 24 million people from falling into poverty by 2030 in addition to saving millions of lives, shows a new study co-authored by Harvard University and Gavi, the Vaccine Alliance.